Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.

Abstract

BACKGROUND IncobotulinumtoxinA has been approved for treatment of glabellar frown lines (GFL) in the United States, all major European markets, South Korea, and Argentina and in Russia and Mexico for the treatment of mimic wrinkles and hyperkinetic facial lines, respectively. OBJECTIVES Prospective, 2-year, open-label, multicenter, repeat-dose, Phase III… (More)
DOI: 10.1111/dsu.12008

Topics

Cite this paper

@article{Rzany2013LongtermRF, title={Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.}, author={B. Rzany and Timothy Corcoran Flynn and Andrea Schl{\"{o}be and Moritz Heinz and Laura S. Harrington}, journal={Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]}, year={2013}, volume={39 1 Pt 1}, pages={95-103} }